Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.22
-8.9%
$0.75
$0.14
$8.30
$251K2.14120,217 shs20,204 shs
Athersys, Inc. stock logo
ATHX
Athersys
$0.00
$0.00
$0.01
$1.99
$286K-0.91.77 million shs6,522 shs
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.02
$0.02
$0.02
$0.50
$97KN/A1,831 shs10,054 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.01
$0.08
$2.14
$7.94M0.688.94 million shs1.00 million shs
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%-15.23%-51.30%-85.87%-95.48%
Athersys, Inc. stock logo
ATHX
Athersys
0.00%+10.48%+3.11%-67.09%-99.47%
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%0.00%-20.16%-33.33%-33.33%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%0.00%-96.97%-97.62%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Athersys, Inc. stock logo
ATHX
Athersys
N/AN/AN/AN/AN/AN/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/A
Athersys, Inc. stock logo
ATHX
Athersys
N/AN/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/A$4.04 per shareN/A
Athersys, Inc. stock logo
ATHX
Athersys
$146K1.96N/AN/A($1.33) per share0.00
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$9.75M0.01N/AN/A($0.40) per share-0.05
ObsEva SA stock logo
OBSV
ObsEva
$20.11M0.00N/AN/A$0.41 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
-$8.63M-$11.01N/AN/AN/A-149.00%-103.79%N/A
Athersys, Inc. stock logo
ATHX
Athersys
-$72.53M-$2.03N/AN/AN/AN/A-223.03%N/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-$39.65MN/A0.00N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A

Latest ATHX, AMPE, OBSV, and CALA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/27/2024Q4 2023
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/A-$2.48-$2.48-$2.48N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/AN/A
Athersys, Inc. stock logo
ATHX
Athersys
N/AN/AN/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/A
2.41
2.41
Athersys, Inc. stock logo
ATHX
Athersys
N/A
0.06
0.06
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
5.73%
Athersys, Inc. stock logo
ATHX
Athersys
19.35%
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/A
ObsEva SA stock logo
OBSV
ObsEva
17.52%

Insider Ownership

CompanyInsider Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
3.30%
Athersys, Inc. stock logo
ATHX
Athersys
0.03%
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
6.60%
ObsEva SA stock logo
OBSV
ObsEva
14.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
61.14 million1.10 millionNo Data
Athersys, Inc. stock logo
ATHX
Athersys
2461.72 million61.70 millionNo Data
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
84.87 million4.55 millionNot Optionable
ObsEva SA stock logo
OBSV
ObsEva
4877.97 million66.74 millionNot Optionable

ATHX, AMPE, OBSV, and CALA Headlines

Recent News About These Companies

ObsEva (NASDAQ:OBSV) Coverage Initiated at StockNews.com
ObsEva Announces Update on Board of Directors
ObsEva SA OBSN
ObsEva SA OBSEF
ObsEva (NASDAQ: OBSV)
ObsEva Annual Report 2022 - Marketscreener.com
ObsEva Annual Report 2022 - Yahoo Finance
ObsEva Annual Report 2022 - Benzinga
ObsEva Annual Report 2022 - EIN News

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Ampio Pharmaceuticals logo

Ampio Pharmaceuticals

NYSE:AMPE
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.
Athersys logo

Athersys

NASDAQ:ATHX
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.
Calithera Biosciences logo

Calithera Biosciences

NASDAQ:CALA
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
ObsEva logo

ObsEva

NASDAQ:OBSV
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.